Physician profile

Jon-Paul Seslar

Foot & Ankle Surgery · San Pablo, CA

NPI 1760410195

$1,081.75

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Foot & Ankle Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$587.96
Food and Beverage$174.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Treace Medical Concepts, INC. $778.91 2022-2023
Medshape, INC. $118.90 2023 Dynanail Helix, Washer, 15 Mm
Wright Medical Technology, INC. $51.73 2019
Stryker Corporation $37.60 2020-2021
Orthofix Medical, INC. $30.85 2023 Physio-Stim
Evolution Surgical, INC $25.01 2021
Bioventus LLC $19.41 2022
Organogenesis INC. $19.34 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jon-Paul Seslar

$1,081.75

in general payments reported 2019-2025

Years
2019-2023
Top company
Treace Medical Concepts, INC.

https://glasscript.com/doctor/498901/jon-paul-seslar

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.